Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Cash from Investing Activities (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Cash from Investing Activities for 13 consecutive years, with $1.5 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Cash from Investing Activities rose 1716.13% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Sep 2024, up 701.2%, and an annual FY2023 reading of $1.3 million, up 797.41% over the prior year.
  • Cash from Investing Activities was $1.5 million for Q4 2023 at Alaunos Therapeutics, up from $1000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $1.5 million in Q4 2023 and bottomed at -$3.8 million in Q4 2020.
  • Average Cash from Investing Activities over 5 years is -$703411.8, with a median of -$135000.0 recorded in 2023.
  • The sharpest move saw Cash from Investing Activities tumbled 5030.0% in 2020, then soared 1716.13% in 2023.
  • Year by year, Cash from Investing Activities stood at -$10000.0 in 2019, then plummeted by 37560.0% to -$3.8 million in 2020, then skyrocketed by 90.47% to -$359000.0 in 2021, then surged by 74.09% to -$93000.0 in 2022, then skyrocketed by 1716.13% to $1.5 million in 2023.
  • Business Quant data shows Cash from Investing Activities for TCRT at $1.5 million in Q4 2023, $1000.0 in Q3 2023, and -$135000.0 in Q2 2023.